导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.63% | 3796/4773 |
| 近一周 | -2.17% | 1379/5462 |
| 近一月 | -5.03% | 2992/5421 |
| 近一季 | -5.19% | 1784/5209 |
| 近半年 | -13.29% | 3837/4920 |
| 近一年 | -9.86% | 3365/4366 |
| 近两年 | 15.55% | 2736/2954 |
| 近三年 | -2.42% | 1963/2253 |
| 成立以来 | 24.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.20% 2182/4961 |
-7.77% 3800/5312 |
- - |
- - |
| 2025 | 8.34% 2905/4813 |
1.29% 1657/3635 |
-2.99% 3400/4076 |
9.26% 3371/4524 |
0.91% 1671/4813 |
| 2024 | 9.26% 1482/3463 |
5.66% 341/2808 |
-4.88% 1580/3014 |
16.00% 1568/3129 |
-6.29% 2642/3463 |
| 2023 | -8.99% 1084/2656 |
6.07% 727/2280 |
-6.88% 1733/2385 |
-0.80% 448/2515 |
-7.12% 2057/2655 |
| 2022 | -18.44% 706/2207 |
-15.72% 1063/1919 |
6.40% 709/2016 |
-11.79% 587/2113 |
3.12% 766/2208 |
| 2021 | -12.32% 1128/1822 |
-1.08% 427/1255 |
-3.47% 1245/1330 |
-10.11% 1211/1466 |
2.16% 674/1822 |
| 2020 | 31.63% 499/1250 |
-13.64% 935/1028 |
14.53% 547/1067 |
12.43% 387/1164 |
18.38% 95/1184 |
| 2019 | - - |
- - |
- - |
1.87% 348/850 |
9.12% 258/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银深证红利ETF联接C VS. 长安沪深300非周期A(740101) |